LSN2463359

Last updated
LSN2463359
LSN2463359.svg
Names
IUPAC name
N-Propan-2-yl-5-(2-pyridin-4-ylethynyl)pyridine-2-carboxamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
EC Number
  • 802-759-0
PubChem CID
  • InChI=1S/C16H15N3O/c1-12(2)19-16(20)15-6-5-14(11-18-15)4-3-13-7-9-17-10-8-13/h5-12H,1-2H3,(H,19,20)
    Key: STAFRSGTRKNXHF-UHFFFAOYSA-N
  • CC(C)NC(=O)C1=NC=C(C=C1)C#CC2=CC=NC=C2
Properties
C16H15N3O
Molar mass 265.316 g·mol−1
Hazards
GHS labelling: [1]
GHS-pictogram-exclam.svg
Warning
H302, H315, H319, H335
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

LSN2463359 is a drug used in scientific research.

Mechanism of action

LSN2463359 is a positive allosteric modulator of the mGluR5, [2] which means it increases the activity of glutamate (an excitatory neurotransmitter) at this receptor.

Contents

Potential uses

A study has found that LSN2463359 and similar drugs can be used as a treatment to some aspects of cognitive deficits in schizophrenia. [3] Another study also mention that it could be used in the treatment of schizophrenia due to the potential interactions between NMDA receptors and mGluR5. [4]

References

  1. ↑ "N-Isopropyl-5-(pyridin-4-ylethynyl)picolinamide". pubchem.ncbi.nlm.nih.gov.
  2. ↑ Gilmour, Gary; Broad, Lisa M.; Wafford, Keith A.; Britton, Thomas; Colvin, Ellen M.; Fivush, Adam; Gastambide, Francois; Getman, Brian; Heinz, Beverly A.; McCarthy, Andrew P.; Prieto, Lourdes; Shanks, Elaine; Smith, Janice W.; Taboada, Lorena; Edgar, Dale M. (January 2013). "In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat". Neuropharmacology. 64: 224–239. doi:10.1016/j.neuropharm.2012.07.030. ISSN   1873-7064. PMID   22884720.
  3. ↑ Gastambide, Francois; Cotel, Marie-Caroline; Gilmour, Gary; O'Neill, Michael J.; Robbins, Trevor W.; Tricklebank, Mark D. (March 2012). "Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator". Neuropsychopharmacology. 37 (4): 1057–1066. doi:10.1038/npp.2011.298. ISSN   1740-634X. PMC   3280638 . PMID   22129780.
  4. ↑ Gastambide, Francois; Gilmour, Gary; Robbins, Trevor W.; Tricklebank, Mark D. (January 2013). "The mGlu₅ positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat". Neuropharmacology. 64: 240–247. doi:10.1016/j.neuropharm.2012.07.039. ISSN   1873-7064. PMID   22884612.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.